Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Locally Advanced Pancreatic Cancer Market Size from 2025 to 2034?
The market size for locally advanced pancreatic cancer has seen swift expansion in the past few years. Projections show an upward trend from $0.95 billion in 2024 to $1.05 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.6%. The escalation in the historical timeframe is primarily due to heightened consciousness about pancreatic cancer, advancement in chemotherapy treatments, burgeoning utilization of targeted therapies, an upward trend in the occurrence of pancreatic cancer, progress in developing combined treatment procedures, and better options for supportive care.
Expectations for the locally advanced pancreatic cancer market reveal a significant expansion aligned for the upcoming years, with projections indicating growth to reach$1.56 billion by 2029 at a compound annual growth rate (CAGR) of 10.4%. The surge predicted throughout this period can be credited to several factors including heightened consciousness about pancreatic cancer, enhancements in chemotherapy regimens, more extensive usage of targeted treatment methods, increased occurrence of pancreatic cancer, the creation of combined treatment guidelines, and improved options for supportive care. Key developments anticipated during this period encompass progress in immunotherapy, the creation of targeted treatments, the evolution of precision radiation methodologies, superior diagnostic imaging, the use of minimally invasive surgical techniques, the implementation of artificial intelligence in treatment strategies, and breakthroughs in combined therapy strategies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
What Are the Core Market Drivers Propelling Growth in the Locally Advanced Pancreatic Cancer Industry?
The growth of markets for locally advanced pancreatic cancer is projected to be spurred by an upsurge in tobacco use. Utilized primarily in products like cigarettes and cigars, tobacco is a plant that contains an addictive ingredient known as nicotine, linking it to serious health concerns such as cancer and heart disease. The escalate in tobacco use has roots in various factors like broad access, cost-effectiveness, marketing of tobacco, social acceptance in certain regions, and stress-induced smoking. Consumption of tobacco significantly contributes to the risk of developing locally advanced pancreatic cancer, hence leading to a higher incidence of pancreatic malignancies. To illustrate, data from the US-based non-profit organization, Global Action to End Smoking, that conducts research aimed at terminating the smoking epidemic indicated that in 2022, around 62.9 million adult tobacco consumers lived in the U.S. This places the U.S. as the 4th global rank and first in the Americas. Moreover, about 11.5% adulte population of the U.S. (28.3 million) smoked cigarettes, with male smokers (13.1%) outnumbering female smokers (10.1%). Consequently, as tobacco consumption escalates, so does the growth of the locally advanced pancreatic cancer market.
How Is the Locally Advanced Pancreatic Cancer Market Segmented?
The locally advanced pancreatic cancermarket covered in this report is segmented –
1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
Which Regions Are Driving the Next Phase of the Locally Advanced Pancreatic Cancer Market Growth?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Locally Advanced Pancreatic Cancer Industry?
The locally advanced pancreatic cancer market is witness to leading corporations actively working towards the creation of innovative merchandise, such as orphan drugs. The objective is to augment the treatment variety, better patient results, and address the unfulfilled medical requirements connected with this harsh illness. Orphan drugs are specifically constructed to cure rare illnesses that impact a minor population and are incentivized by governmental bodies via benefits like tax deductions and market exclusivity to encourage their growth. To illustrate, Actuate Therapeutics Inc., an American biopharmaceutical enterprise, declared in January 2025, that its creation Elraglusib, a fresh GSK-3ß inhibitor, has earned Orphan Drug Designation from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA). This is for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a probable type of locally advanced pancreatic cancer). This acknowledgment underlines its potential to bridge a crucial gap in the treatment of this severe cancer, especially after the promising Phase 2 trials demonstrated significant clinical advancements and anti-tumor impacts in metastatic PDAC patients.
View the full report here:
How Is the Locally Advanced Pancreatic Cancer Market Defined and What Are Its Core Parameters?
Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model